Albumedix, the world leader in recombinant human albumin, announced today the strengthening of its Executive Leadership with the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy.

Increase cell performance; address logistical challenges with an optimized cryopreservation solution as presented by Phil Morton, Chief Technology Officer within Albumedix

After 13 years leading the company, Peter Rosholm has decided to step down as CEO and handover the company’s leadership. Peter Rosholm will formally hand over his responsibilities as CEO on July 1st, 2020 to his successor Jonas Skjødt Møller who has been Chief Operating Officer since the management buyout in 2018.

Albumedix' Chief Technology Officer, Phil Morton, contributed his thoughts on trends and the impact of evolving technology in a recent PharmaVoice feature focusing on ´Commanders & Chiefs´

Albumedix are thrilled to be able to continue supporting the Nottinghamshire Wildlife Trust in their endeavours to protect and restore the beautiful environment and wildlife both on our doorstep and across the region.

Amidst the uncertainty and stress of this unprecedented time, it’s easy to feel a dip in morale. No longer being able to nip for a cup of tea with colleagues or have a lunchtime catch up in one of our busy kitchen areas, a sub-team within Albumedix formed to capture ideas that would protect our extremely supportive company culture.

The cell and gene therapy industry has, over the past years, proven its potential and many patients are now benefitting from advanced therapies with dramatic clinical results. Increasing clinical activity in diverse and more prevalent indications is prompting considerable effort and progress in addressing various manufacturing and logistical challenges in order to make more practical and scalable therapies.

One of our valued medical device partners in the UK, Chalice Medical, is working around the clock to handle the huge surge in demand of their ECMO devices (oxygenators / life support machines). This surge has come as a result of the Covid-19 pandemic. In response, Albumedix is doing all we can to prioritize their shipments and any others related to the outbreak of the virus.

Albumedix, the world leader in recombinant human albumin, announced today that the Center for Biologics Evaluation and Research (CBER), one of six main centers for the U.S. Food and Drug Administration (FDA), has accepted a Drug Master File (DMF) submission for the company’s Recombumin® Elite.

As a global provider of recombinant human albumin for the life science industry, Albumedix are fully dedicated to ensuring a stable product supply to our customers in all regions of the world. As such, we are actively monitoring and responding to the potential impact of the Coronavirus disease (COVID-19) outbreak.

Albumedix is a world leading manufacturer of recombinant human albumin (rHA), and as such our manufacturing plant is the core of our business. As a company, we talk a lot about our rHA products, how they’re useful in different applications and what benefits they can bring to final therapies for patients worldwide. However, we don’t talk as much about the amazing people within our business that make the magic happen.

In December, Albumedix held a 'Capping off Ceremony' to celebrate the brand new, four-storey manufacturing plant extension being confirmed as watertight!